The peptide salamandrin-I modulates components involved in Pyroptosis and induces cell death in human leukemia cell line HL-60

• Autor(a) principal: Carvalho, Amandda Évelin Silva de
• Data de Publicação: 2023
• Outros Autores: Oliveira, Nakaly Natiely de, Machado, Julia Viana Lafetá, Moreira, Daniel Carneiro, Brand, Guilherme Dotto, Leite, José Roberto de Souza de Almeida, Plácido, Alexandra, Eaton, Peter, Araújo, Felipe Saldanha de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UnB
• Texto Completo: http://repositorio2.unb.br/jspui/handle/10482/48493; https://doi.org/10.3390/pharmaceutics15071864; https://orcid.org/0000-0003-1961-7281; https://orcid.org/0000-0002-1096-3236; https://orcid.org/0000-0003-1821-1992
• topic: Peptídeos; Antioxidantes; Salamandra; Leucemia; Piroptose; Anfíbio

Amphibian secretions have been extensively investigated for the production of bioactive molecules. Salamandrin-I is an antioxidant peptide, isolated from the skin secretion of the fire salamander, that has induced no toxicity in microglia or erythrocytes. Importantly, the administration of antioxidants may constitute an adequate therapeutic approach to cancer treatment. Here, with the purpose of better characterizing the therapeutic potential of salamandrin-I, we investigated whether this antioxidant peptide also exerts anticancer activity, using the human leukemia cell line HL-60 as a cancer model. Salamandrin-I treatment induced a significant reduction in HL-60 proliferation, which was accompanied by cell cycle arrest. Furthermore, the peptide-induced cell death showed a significant increase in the LDH release in HL-60 cells. The cellular toxicity exerted by salamandrin-I is possibly related to pyroptosis, since the HL-60 cells showed loss of mitochondrial membrane potential and hyperexpression of inflammasome components following the peptide treatment. This is the first demonstration of the anticancer potential of the salamandrin-I peptide. Such results are important, as they offer relevant insights into the field of cancer therapy and allow the design of future bioactive molecules using salamandrin-I as a template.